What Is Retatrutide?

1. What Is Retatrutide?

Retatrutide is an investigational molecule being developed by Lilly. Lilly describes it as a once-weekly triple hormone receptor agonist that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

Retatrutide is not simply “another GLP-1” in the same way semaglutide is a GLP-1 receptor agonist. It is also different from tirzepatide, which is a dual GIP and GLP-1 receptor agonist. Retatrutide adds glucagon receptor activity to the GIP and GLP-1 receptor combination.

Key terms:

For broader receptor-language background, see GLP-1 vs GLP-2 vs GLP-3 and What Is a GLP-1?.

2. Why Is Retatrutide Called a Triple Agonist?

Retatrutide is called a triple agonist because it activates three receptor pathways: GIP, GLP-1, and glucagon. That wording is more precise than calling it a GLP-1 medication, even though GLP-1 is the term most people recognize from semaglutide and tirzepatide.

The term “GLP-1” is often used as a catch-all for injectable metabolic drugs, but retatrutide does not fit neatly into this category. The current receptor stack looks like this:

For related molecule explainers, see What Is Semaglutide? and What Is Tirzepatide?.

3. Is Retatrutide FDA-Approved?

No. Retatrutide is not FDA-approved as of October 15, 2026. Lilly states that retatrutide is investigational, has not been approved by any regulatory agency, and is legally available only through Lilly clinical trials. Since June 2026, Lilly has also listed a pre-approval expanded access program on ClinicalTrials.gov. It is single-patient, must be requested by a treating physician, and is limited to adults with a BMI ≥35 despite the highest available dose of approved weight-management therapy, two or more serious obesity-related complications, and no access to a retatrutide trial.

Phase 2 and Phase 3 trial results demonstrate research progress, but they do not equal FDA approval or public availability. Lilly has also warned against counterfeit or compounded products sold online claiming to be retatrutide. FDA warning letters have called online “research use only” retatrutide unapproved new drugs.

• Retatrutide is a research molecule.
• Lilly is studying it in Phase 3 programs.
• It is not an approved, FDA-labeled medication.

Lilly’s July 23, 2026 update set a plan to submit a Biologics License Application to the FDA in January–March 2027, and its September 29, 2026 release repeated that timing. As of October 15, 2026, no submission had been announced. This is a filing forecast, not a confirmed approval or launch date.

4. What Did the Phase 2 NEJM Study Show?

A 2023 New England Journal of Medicine Phase 2 article studied retatrutide in adults with obesity or overweight, without type 2 diabetes. Lilly’s summary of the data noted that retatrutide achieved up to 17.5% mean weight reduction at 24 weeks and up to 24.2% at 48 weeks in the highest-dose group.

The study suggested substantial weight reduction in the tested population, and researchers noted weight had not plateaued by the end of the 48-week treatment period. Gastrointestinal adverse events were the most common side effects, generally occurring during dose escalation.

While promising, Phase 2 data is meant to guide larger Phase 3 trials, not establish safety and efficacy for broad public use.

5. What Did TRIUMPH-4 Report?

Lilly’s December 11, 2025 TRIUMPH-4 press release described a Phase 3 trial in adults with obesity or overweight and knee osteoarthritis, without diabetes. Participants in the highest retatrutide arm lost an average of 28.7% of body weight, or 71.2 pounds, at 68 weeks under the efficacy estimand, compared with 2.1% weight loss with placebo.

TRIUMPH-4 was not a general public weight-loss survey. ClinicalTrials.gov describes NCT05931367 as a randomized, double-blind, placebo-controlled Phase 3 study asking research questions about both weight and knee osteoarthritis outcomes in a highly defined study population.

TRIUMPH-4 trial details:

These results apply specifically to trial participants and do not guarantee similar outcomes or eligibility for the general public.

6. What Is TRANSCEND-T2D-1?

TRANSCEND-T2D-1 is Lilly’s Phase 3 type 2 diabetes topline readout for retatrutide, announced on March 19, 2026. It was a 40-week randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes and inadequate glycemic control using diet and exercise alone.

Lilly reported that retatrutide met the primary endpoint and key secondary endpoints versus placebo. The press release noted average A1C reductions up to 2.0 percentage points across retatrutide arms and average weight loss up to 36.6 pounds, or 16.8%, at 40 weeks.

Retatrutide is being studied for multiple conditions, not just obesity. Lilly’s Phase 3 clinical trials also include knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Lilly’s June 6 update confirmed publication of TRANSCEND-T2D-1 in The Lancet. Publication does not establish an approved indication.

7. What Did the 2026 TRIUMPH Results Add?

Lilly’s May 21 report added 80-week evidence from TRIUMPH-1:

The treatment-regimen analysis, which includes outcomes regardless of adherence, gave 25.0% weight loss for 12 mg versus 3.9% for placebo. This intention-to-treat result is the primary weight analysis in the peer-reviewed TRIUMPH-1 paper, published in the New England Journal of Medicine on September 29, 2026. In that dose group, nausea occurred in 42.4% versus 14.8% with placebo, and adverse events led to discontinuation in 11.3% versus 4.9%. Earlier data: June results and safety report

The NEJM paper also reported the two nested sub-studies. In 574 participants with knee osteoarthritis, the WOMAC pain score fell by 3.5 points on 9 mg and 3.6 points on 12 mg versus 1.9 on placebo. In 243 participants with obstructive sleep apnea, the apnea-hypopnea index fell by 34.3 and 31.7 events per hour versus 9.9 on placebo. Both sub-studies met their primary endpoints.

Lilly’s July report added two 80-week Phase 3 results under the efficacy estimand:

Full TRIUMPH-2 results were published in The Lancet on September 29, 2026. Under the paper’s primary treatment-regimen estimand, weight fell 18.8% on 12 mg versus 5.1% on placebo at 80 weeks. TRIUMPH-3 has been reported only in Lilly’s topline release so far.

TRIUMPH-3 was not designed to prove heart protection: major adverse cardiovascular events were numerically lower with retatrutide (hazard ratio 0.82, 95% CI 0.55–1.22) but not statistically significant, and a dedicated cardiovascular and kidney outcomes trial is still running, with primary completion estimated for 2029. These are different study populations; their weight-loss percentages should not be treated as a ranking.

8. Why “GLP-3” Is an Awkward Nickname

“GLP-3” is an informal nickname that tries to compress retatrutide into a memorable phrase. Lilly’s FAQ calls GLP-3 scientifically inaccurate and notes that “triple agonist” is the more suitable term because it reflects the three specific receptor targets.

The nickname is understandable: people already know GLP-1, tirzepatide is often explained as dual GIP/GLP-1, and retatrutide adds a third pathway. “GLP-3” sounds like a logical sequel, but it is not a formal receptor category or approved class name.

• Retatrutide is the name of the molecule.
• Investigational describes its regulatory status.
• Triple GIP/GLP-1/glucagon receptor agonist is the accurate mechanism description.
• “GLP-3” is just informal public shorthand.

9. What Is Retatrutide FAQ

• What is retatrutide in simple terms?

  Retatrutide is Lilly's investigational triple hormone receptor agonist. It is designed as a single molecule that activates receptors for GIP, GLP-1, and glucagon.

• Is retatrutide FDA-approved?

  No. Lilly states that retatrutide is investigational, not currently approved by the FDA, and legally available only through Lilly clinical trials. Since June 2026 Lilly has also listed a physician-requested, single-patient expanded access program limited to adults with severe, treatment-refractory obesity who cannot join a trial.

• Why do people call retatrutide a triple agonist or GLP-3?

  Triple agonist is the more accurate shorthand because retatrutide targets three receptor pathways: GIP, GLP-1, and glucagon. GLP-3 is an informal media nickname, not an official scientific drug class.

• What did the TRIUMPH-4 press release report?

  Lilly's December 2025 TRIUMPH-4 press release described a Phase 3 trial in adults with obesity or overweight and knee osteoarthritis. Lilly reported average weight loss up to 28.7%, or 71.2 pounds, at 68 weeks in the highest retatrutide arm.

10. Sources